Welcome To Eleszto Genetika

Unlocking Economics through

Synthetic Biology

EGHomePict_2

Creating High-Value Molecules via Fermentation

Eleszto Genetika is a world leader in the genetic modification of yeast and other microbial platforms for the production of high-value target molecules. We work diligently and efficiently with our partners to help identify and create novel and efficient metabolic pathways to unlock greater value.

The Right Team for the Job

United & Experienced Team

United team atmosphere, minimal turnover, maximum focus on customer needs. Majority of team with 10+ years at the company, experience with filamentous fungi, yeast and E. coli.

New Technology

Continuously improving technology and adding new innovations (incl. HTP construct building, HTP strain building, HTP screening and HTP analytics)

Recent additions: in house NGS sequencing capability

Our Knowdelge

High Throughput Thinking, Proteomics, Targeted Metabolomics used routinely. We Transfer knowledge from filamentous fungal work to yeast

Automatization

High level of automatization, database based data storage and visualization, automated routine workflows

Cost Effective

Efficient and cost-effective operation, POC based approach

Teamwork

Highly developed problem solving skills, well structured, excellent teamwork

Current Projects News

Cannabinoids- Parallel

BUDAPEST, Hungary and ATLANTA, June 18, 2019 /PRNewswire/ -- Intrexon Corporation (Intrexon) (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve quality of life and health of the planet, and Surterra Wellness (Surterra), one of the fastest growing health and wellness companies in the United States today announced an exclusive global licensing agreement.  The companies will join forces to advance Surterra's cannabinoid production at a reliable, efficient, cost-effective, industrial scale utilizing Intrexon's proprietary yeast fermentation platform...

Read More

UDCA- Arch

BUDAPEST, Hungary, Oct. 23, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and Arch Pharmalabs Ltd., a world-class provider of small molecule process chemistry and full life-cycle active pharmaceutical ingredients (API), today announced they have entered into an exclusive collaboration to develop microbial strains for fermentation-based production of an API currently sourced from animals...

Read More

Opiates- Genopaver

Researchers want to engineer yeast to synthesize various opiates instead of depending on opium poppies to generate them. Poppy farming is a dangerous business that can lead to illicit drug sales and risks losing key materials to crop failure. To engineer the yeast, though, scientists need to find all the enzymes that poppies coordinate to make opiates...

Read More

Reference Page

Sanofi

SAN CARLOS, Calif., Sept. 2, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has entered into an Exclusive Channel Collaboration (ECC) with Sanofi Chimie, a wholly owned subsidiary of Sanofi (EURONEXT: SAN and NYSE: SNY) to develop an enhanced production process for a specific family of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi's current manufacturing operations in France. This collaboration will leverage Intrexon's proprietary technology suite plus Sanofi's expertise and innovation in yeast metabolism and industrial chemistry to increase overall yield....

Read More

Peptide Expression Platform Development

BUDAPEST, Hungary, June 13, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and Johnson Matthey (LN: JMAT), a global leader in science that enables cleaner air, improved health and more efficient use of natural resources, today announced they have entered into an exclusive collaboration focused on the development of microbial strains for fermentative production of peptide-based active pharmaceutical ingredients...

Read More
Scroll to Top